Next Phase Newsletter

A private equity firm founded in 2001 and headquartered in San Francisco California recently closed its 3rd fund at $310 million. The firm makes growth equity investments ranging from approximately $15 to $40 million over the investment’s lifetime. The firm primarily invests within the United States but is open to consider international investment as well.

The firm is currently looking for commercial stage companies in areas of medical technology and devices, life science instruments and tools, healthcare IT, healthcare services, agriculture and animal health. The firm is agnostic in terms of therapeutic indication.

The firm only invests in companies with commercial revenue. The firm supports organic growth strategies, which allow for gross profit growth and investment in product pipelines and commercial expansion. The firm looks to take a seat on the company board and prefers to be the lead or sole institutional investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture fund of a multinational healthcare company has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. The fund is an evergreen fund and makes equity investment in early-stage biotech therapeutic and diagnostic companies. The fund prefers Series A. The typical initial investment size ranges from CHF 1-5M with capital reserved for follow-on financing. The fund invests in companies that are based in Europe, North America, and the Pacific Region. The fund is actively seeking new investment opportunities.

The Fund is looking to invest in companies with innovative new technologies, medicines or diagnostics, particularly in the areas of interest to the fund’s parent company. This includes: Oncology, Central Nervous System, Inflammation, Anti-Infectives, Virology, in-Vitro Diagnostics, Diabetes Care, and Molecular Diagnostics. For therapeutic biotech, the fund is willing to invest in companies that are still 18-24 months away from the clinic. The fund highly prefers companies with both a discovery engine and a product pipeline.

The Fund invests in private and public companies. The fund only invests in public companies as part of a collaboration entered into by the parent company’s pharma or diagnostics division. The fund requests board seats and typically prefers to be in an ownership range of 15% or more. In general, the fund prefers to co-invest with leading venture funds as well as other corporate venture funds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices throughout Europe, The US and the Middle East has approximately €540M AUM and is currently managing five active funds. The firm’s fifth fund had its first close at €92M in October 2014, with the aim to raise €150-200M. The firm makes equity investment in life sciences and biomedical technology companies at all stages of development. However, the firm prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €3M to €7M. The firm looks for companies that are based in the US, Canada, Israel, and Europe. The firm is actively screening new investment opportunities.

The firm is generally opportunistic in the life sciences space. The firm targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and is open to all indications including orphan indications. In medical devices, the firm has a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The firm invests in companies at all stages of their development. For drug development, the firm invests from late preclinical to mid-stage clinical development. The firm sometimes considers companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital branch of a drug retailing chain looks to make strategic equity investments into companies of up to $5 million. The firm is generally stage agnostic although they prefer companies at or near commercialization. The firm is actively reviewing new investment opportunities and is open to consider companies from around the globe.

The firm is focused on investing in companies of mutual strategic benefit to the parent company. This includes companies in sectors of Medical Devices, Point of Care Diagnostics, Healthcare Services, Pharmacy Innovation, and Sensors/Wearable devices. For medical devices and diagnostics the company prefers products that are near or have reached commercialization as the firm can add significant strategic value in distribution, marketing and sales. The firm is also very interested in products that will be sold directly to patients or devices/diagnostics that will be able to be used in the firms clinics. For wearable devices and sensors the firm is most interest in technologies with clinical value in terms of disease treatment and/or management.  The firm is open to all indication types.

The firm is looking for privately held companies with experienced management teams. The firm looks to take a board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An innovative private equity firm utilizing a virtual pharma (asset centric) model is looking to in-license early stage pharmaceutical assets, and is capable of providing $15-$20 million, or more, to get a project through proof of concept. The firm prefers to in-license or acquire individual pharmaceutical assets and is much less likely to make traditional equity investments into companies. Ideal candidates have yet to receive significant VC funding and the firm prefers to invest without syndicates. The firm integrates the founders and their company into a special purpose vehicle and works with them in a very close collaborative way to maximize the product value. The firm is interested in investing in projects around the globe and is capable of making 10+ investments over the course of the next year if enough high quality investments present themselves.

The firm is looking primarily for pharmaceutical assets and to a much lesser extent diagnostics and medical devices. The firm is willing to invest in assets that are as far as 12-18 months pre-IND to those that are early in phase I of clinical trials and ideal candidates are IND ready and preparing to enter phase I. The firm is open to all therapeutic areas and indications where proof of concept can be shown in early clinical trials. For medical device and diagnostic opportunities only very select programs of extreme appeal will be considered.

The firm is looking to partner with management teams that have an extreme understanding of the science behind their product that are willing to operate in a virtual environment. The firm acts as an extremely hands on investor often integrating investments into the parent company and ensuring that all assets are developed in the most effective manner with high focus on early development de-risking.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An institutional alternative investor based in France manages an internal division dedicated exclusively to direct investments in the life sciences. The firm is currently investing out of its 4th fund which recently closed at $250 million bringing its total assets under management to over $1 billion. The firm invests anywhere from $2 to $20 million into its portfolio companies and is capable of investing into approximately 10 companies from its 4th fund. The firm looks to act as the lead investor into companies providing equity capital and assuming approximately a 20% shareholding. The firm is looking to invest primarily in companies based in Europe but has 20% of its portfolio dedicated to global investments.

The firm is looking for companies developing Therapeutics, Medical Devices and Molecular Diagnostics. The firm is open to the spectrum of subsectors and indications; however it is reluctant to allocate to cell or gene therapy and has significant experience in diabetes so companies targeting this indication are of special interest. The firm also is willing to consider companies targeting orphan indications. For therapeutics companies the firm is looking for opportunities in early Phase I or later. For medical devices the company must have some in human data to be considered.

The firm looks to have strong involvement in the firm’s management team and hold positions on the company’s Board. The firm looks to hold investments for 2-6 years before selling shares, generally to a large company that will finalize the products commercialization. Companies located outside of Europe are often recommended and advised by the firm on opening up subsidiaries in Europe using the firm’s vast European network

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital company founded in 1996 with offices in the US and Europe is currently making investments out of its vintage 2012 $200 million life science focused fund. The fund is backed 50% by two large pharma companies who are members of the fund’s scientific advisory board. The firm’s investment size is variable although they look to invest in companies who are able to reach a substantial value inflection point and exit with $15-$20 million in total investment over 4-6 years. The firm is looking for companies located around the globe. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in companies developing therapeutics. The firm is generally agnostics across indication areas and technology types and is open to reviewing small molecules and biologics as well as cell and gene therapy. The firm is looking for companies with a lead asset anywhere from the Pre-clinical phase to Phase II of clinical trials. The firm’s main investment strategy is to back/create virtual companies focused around a single therapeutic asset. The firm is able to invest in particularly early stages of companies working with antibodies and biologics as they have significant domain expertise in these areas. For companies working with novel mechanisms of action the firm requires there be a strong understanding of the underlying sciences, and for companies working with pre-existing pathways or technologies there must be clear evidence of differentiation.

The firm is looking for companies where the founders have some involvement, either in management or as advisors/consultants to ensure the project as the scientific support required to succeed. The firm looks to play an active role in companies and takes a board seat following investment. The firm is willing to invest in both private and publically held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com